On Friday March 25th, our developing partner Iconovo for the Covid-19 vaccine device, published thePress Release linked below. #isr #iconovo #covid_19 #drypowdervaccine #fullspikevaccine #intranasal #bangladesh #ISR52 mfn.se/a/iconovo/icon…

Last week, Redeye initiated analyst coverage for ISR. redeye.se/research/83973…

From yesterdays presentation at Redeye AW in Malmö. redeye.se/video/event-pr…

After participating the lsxleaders.com/lsx-world-cong… in London, we’ve attended the Redeye AW in Malmoe this week. A lot is happening now, in preparing for the clinical phase for ISR52 and the development of other products in our pipeline. Wishing you all a fantastic weekend❤️🥂

ISR’s taking important steps in scaling up production for future needs to the ISR052 - or dry-powder intranasal Covid-19 vaccine: mb.cision.com/Main/15466/357…

Press Release from our partner Iconovo today: storage.mfn.se/d6723710-d7dc-…

Today, we’ve published the Annual Report for 2021 with a new and more illustrative and attractive layout. We hope you’ll like it! israb.se/assets/ISR-Ars…

Redeye Growth Day June 2nd, ISR presentation with our CEO Ola Winqvist for preview, which will be followed by live a interview/discussion led by our Redeye analyst, Ethel Luvall, external sector specialist and our CEO Ola. redeye.ifairs.com/#/booth?id=723

ISR-052 provides long-term protection against SARS-CoV-2 mb.cision.com/Main/15466/357…

One step further in the process towards an intranasally inhaled, dry-powder solution for SARS-CoV-2 vaccine to humanity news.cision.com/isr/r/delegati…

With the approval from BMRC NREC, we are taking significant steps, and keeping pace in order to have ”first-patient-in” in Q4 2022, for our dry-powder nasally inhaled SARS-CoV-2 vaccine - ISR 052. news.cision.com/isr/r/sars-cov…

Half Year Report for 2022 is postponed due to a heavy workload from parallel activities. New date is set to August 31 news.cision.com/se/isr/r/nytt-…

One important step in the development of an effective treatment within HIV, by the closing of inclusion of new patients. Next step is the closing of the trial, which will be in late 2022. news.cision.com/se/isr/r/isr-h…

Report for the 1st half of 2022: mb.cision.com/Main/15466/362…

Link to our Chief of Clinical Operations, Nigel Goodmans presentation at yesterdays Redeye event: redeye.se/video/event-pr…

Link to yesterdays conference call in regards of the financial report for the 1st half of 2022 financialhearings.com/event/44262

Redeye’s CEO interview with Ola Winqvist: eur04.safelinks.protection.outlook.com/?url=https%3A%…

Next week, on October 23rd, our partner Iconovo arranges this symposia, where- among others - our CEO Ola Winqvist will present: mediconvillage.se/sv/evenemang/m…

Unfortunately we published the wrong date for this event. Corrected below. Next week, on October 25th, our partner Iconovo arranges this symposia, where- among others - our CEO Ola Winqvist will present: mediconvillage.se/sv/evenemang/m…

Presentation by Nigel Goodman (Head of Clinical Operations at ISR) from last weeks symposium in Lund: youtu.be/4tEr7q3fZ04